#USA #Burlington #Consano Bio #C-1101 #Chronic Sciatica

Consano Bio Secures $15 Million in Oversubscribed Financing

Consano Bio, Inc., a biotechnology firm focused on developing groundbreaking therapeutics for severe orthopedic conditions, has successfully raised over $15 million in a financing round that exceeded its original target. This capital infusion aims to propel the clinical development of C-1101, the company’s lead investigational therapy.

Relieving Chronic Sciatica

C-1101 is a potential first-in-class treatment designed to address chronic painful lumbosacral radiculopathy (LSR), more commonly known as chronic sciatica. This condition affects many individuals, manifesting as debilitating lower back pain that radiates towards the legs due to damage or irritation of spinal nerve roots. It is a condition that burdens countless Americans, driving extensive healthcare costs and contributing to a growing reliance on opioid therapies.

With this latest financing, Consano Bio has raised a total of over $45 million since its inception three years ago, showcasing strong investor confidence in their innovative approach. The funds will facilitate the completion of the ongoing Phase 1 clinical trial (C-1101-101) and further develop the scientific framework and intellectual property associated with C-1101 and other product candidates.

The Clinical Journey Ahead

The Phase 1 trial is currently enrolling participants suffering from chronic LSR in both the United States and Australia, with enrollment expected to conclude in early 2027. The anticipated clinical data from this trial will pave the way for the next phases of development. Notably, the U.S. FDA has granted C-1101 Fast Track designation, highlighting the urgent need for effective treatments in this domain.

A Critical Need in Pain Management

Chronic sciatica remains a substantial public health issue, and its economic implications cannot be overstated. The condition is responsible for an astronomical $135 billion in U.S. healthcare spending annually, making it a leading cause of disability and chronic pain management issues. Currently, there are no FDA-approved pharmaceutical options for chronic sciatica, leaving many patients reliant on inadequate care that fails to address their underlying issues.

Andrew Hall, CEO of Consano Bio, expressed optimism about C-1101’s potential. He remarked, “C-1101 represents a new category of disease-modifying biologics aimed at activating cellular repair, ultimately alleviating pain and dysfunction stemming from orthopedic conditions. Our focus on LSR is only the starting point, as we believe this innovative approach can be transformative in treating various related conditions.”

Understanding C-1101

C-1101 is unique in its formulation, derived from platelet-rich plasma, designed to modulate inflammation and enhance cellular repair where it’s most critical. Administered via epidural injection, this therapy aims to deliver high concentrations of vital growth factors, cytokines, and matrix proteins directly to the site of nerve injury, promoting accelerated recovery.

Looking to the Future

As Consano Bio continues its clinical trials and focuses on the developing C-1101, the biotechnology firm is poised to play a pivotal role in changing the landscape of treatments for chronic pain, especially for conditions like LSR. This innovative approach could potentially usher in a new era of pain management that not only addresses symptoms but also targets the root causes of the condition.

About Consano Bio

Founded with the mission to revolutionize the treatment of painful orthopedic disorders, Consano Bio operates from the Greater Boston area, leveraging cutting-edge science to develop therapeutic options that enhance healing and improve patient quality of life. For further details on their innovative therapies and ongoing research, visit Con sano Bio's website.